税务信息监测+政策执行上强度。 今年3月以来，不少投资港股美股的中国居民收到当地税务部门通知，被提示自查个人境内外所得并及时进行纳税申报。在社交平台上，部分纳税人发帖分 享称，自己已赶在6月30日前按照20%税率完成了跨境投资收入的个税缴纳。 中国全球征税一直有法律依据。不过，据第一财经记者多方了解，相比往年，今年相关的纳税及补税通知较往年更为密集、覆盖面更大，通知形式包括短 信、电话等。 多位税法人士对记者表示，中国对个人境外所得征税的法律依据没有变化，但过去因为种种原因执行力度有限。随着CRS（共同报告标准）朝着更深、更广 的维度落实，加上中国跨境投资监控尤其逃避税行为监测的技术进步、政策强化，全球征税的执行力度加大是趋势。据记者了解，多数收到上述通知的纳税 人会被追溯3年（以内）即2022年～2024年的境外所得及纳税情况。 有律师表示，今年3月以来收到补税通知的跨境投资者增多，可能与年度汇算清缴期窗口，我国反避税政策加强、对资本外流管控强化，以及技术手段进步 强化逃避税监测、促进税务合规等多个因素有关。 在某社交媒体上，晒帖说收到类似补税通知的网友还有不少，IP地址或帖子中提及的纳税地包括北京、上海、 ...

在 2025年6月17日-19日圆满举办的"2025 制造业数字化博览会"上，快递100携「百递云·企业快递管理 SaaS」——一站式企业快递物流管理平台惊艳亮相。展会闭幕次日，快递100团队便马不停蹄地走进重 要合作伙伴——哈啰集团总部，展开了一场聚焦产品落地成效与客户真实体验的深度回访。 此次走访正值哈啰邮局正式上线「百递云·企业快递管理SaaS」系统两个月之际。快递100深入一线倾听 客户声音，全面了解系统在实际运行中的表现。在面对面交流中，哈啰方面对系统的高效性、稳定性及 用户体验给予了高度评价，充分认可了其在提升内部快递管理效率、优化员工服务体验方面的显著价 值。 同时，来自邮局负责人、邮局管理员和员工的真实反馈也为快递100的产品迭代提供了鲜活、宝贵的实 践依据。这些源自现场的第一手信息，不仅印证了「百递云·企业快递管理SaaS」在复杂业务场景下的 适应力与可扩展性，更彰显了快递100"客户为先"的价值观——将客户需求置于产品演进的核心位置， 用持续优化回应真实场景，用技术温度赋能企业管理升级。 缘起：从需求探寻到合作萌芽的起点 哈啰作为国内专业的本地出行及生活服务平台，致力于应用数字技术的红利， ...

新华社北京7月4日电（记者李恒）即将迎来小暑节气，我国大部分地区气温持续升高，雷雨多发， 空气湿度逐渐增加，健康问题备受关注。4日，国家卫生健康委以"时令节气与健康"为主题举行新闻发 布会，围绕三伏贴使用、腹泻治疗等话题，为公众健康过夏提供指引。 三伏贴作为中医"冬病夏治"的代表疗法，近年来广受欢迎。中国中医科学院西苑医院主任医师王凤 云介绍，三伏贴适用范围包括受凉以后就容易发作或者在冬季容易反复发作的疾病。儿童贴敷时间不宜 过长，一般以0.5小时到2小时为宜，要密切观察孩子皮肤反应情况，如果有过敏要及时停用；老年人使 用三伏贴时，若出现皮肤红肿、瘙痒等不适，应立即停用，必要时咨询医生；孕妇禁用三伏贴。 腹泻问题，夏季高发。北京协和医院主任医师李景南指出，多数情况下，腹泻的发生与肠道内环境 紊乱密切相关。补充益生菌对于改善肠道菌群、调节肠道内环境紊乱可以起到一定的辅助作用。 近年来，每逢暑假，医疗美容就迎来一波热潮。中国医学科学院整形外科医院主任医师王永前提 示，医疗美容的本质是医疗行为，要充分了解医疗美容项目的风险和实际效果。前往医疗机构、使用正 规的产品和器械，可以大大降低风险，但不建议未成年人接受医美手 ...

Corporate Presentation March 2024 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ability to successfull ...

编号：20250702 投资者关 系活动类 别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □√ 现场参观 □ 一对一沟通 □其他 参与单位 名称及人 员姓名 中信证券、信达证券、大成基金、国投瑞银、华安基金、 淡水泉投资等 13 人 时间 2025 年 7 月 2 日 地点 公司会议室 上市公司 接待人员 董事会办公室 投资者关 系活动主 要内容介 绍 一、参观公司展厅及臻宝博物馆； 二、问答环节： 各方还就开店情况、海外门店情况、珠宝产品系列情况、新品 规划情况、产品结构情况、电商业务等内容进行了交流，可参阅公 司已披露公告、互动平台问答和前次活动记录表之问答。 交流过程中严格按照有关制度规定，没有出现未公开重大信 息泄露等情况。 附件清单 无 | | | 证券代码：002345 证券简称：潮宏基 广东潮宏基实业股份有限公司投资者关系活动记录表 ...

Core Viewpoint - A lawsuit has been filed against Compass Diversified Holdings and its executives for potential violations of federal securities laws, stemming from material misstatements in financial statements related to its subsidiary, Lugano Holdings, Inc. [1][3][4] Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Matthews v. Compass Group Diversified Holdings, Inc., et al., No. 25-cv-981 [2] - Investors have until July 8, 2025, to request to be appointed to lead the case [2] Group 2: Financial Misstatements - Compass admitted that its fiscal 2022-2024 financial statements contained material misstatements regarding unrecorded financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable for Lugano [3] - On May 7, 2025, Compass announced that investors should not rely on its fiscal 2024 financial statements due to an ongoing internal investigation, leading to a stock price decline of approximately 62%, from $17.25 to $6.55 per share [4] - On June 25, 2025, Compass further advised that investors should not rely on its fiscal 2022 and 2023 financial statements amid the ongoing investigation [5] Group 3: Legal Representation - Bleichmar Fonti & Auld LLP, a leading law firm in securities class actions, is representing the plaintiffs in this case [7] - The firm operates on a contingency fee basis, meaning there are no upfront costs for shareholders [6]

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's handling of Medicaid eligibility redeterminations and its financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Company Operations and Allegations - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits, which were paused during COVID but resumed in 2023 [3]. - The company claimed to be monitoring cost trends related to the Medicaid redetermination process and believed its negotiated rates were adequate for the risk profiles of Medicaid patients [4]. - Contrary to these claims, the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 3: Stock Performance and Financial Impact - Following Elevance's announcement on July 17, 2024, regarding increased Medicaid utilization, the stock price fell by $32.21, or nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, or nearly 11%, from $496.96 to $444.35 per share [7].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...